Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Kessler likely to retire from the FDA:

This article was originally published in Clinica

Executive Summary

After six years as commissioner of the US FDA, The Washington Times reports that David Kessler intends to join the exodus of top-level officials from President Clinton's administration. Dr Kessler has been assiduous in efforts to have nicotine classified as a drug and thus made subject to regulation. He has also led attempts to speed the agency's approvals processes for drugs and devices. Dr Kessler's spokesman told Clinica that the commissioner's departure was not imminent, but that Dr Kessler had accomplished all his long term goals for the agency.

You may also be interested in...



A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

Go-Ahead For Appointment Of European Union Reference Labs For IVDs

EURLs have been a critical missing element of the IVDR for assessing the higher-risk class D IVDs. Two new implementing regulations, on fees and tasks, bring them closer to designation.

Stock Watch: Protocol Changes Preface Poor Trial Outcomes

It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?

Topics

Latest News
UsernamePublicRestriction

Register

MT089514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel